Abiraterone (CB-7598, CB7598, CB 7598) is a potent steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase (CYP17) inhibitor with an IC50 at 4 nM. Abiraterone (CB-7598, CB7598, CB 7598) is currently undergoing phase II clinical trials as a potential compound for the treatment of prostate cancer. In preclinical studies, abiraterone (CB-7598, CB7598, CB 7598) has demonstrated the ability to selectively inhibit the target enzyme, resulting in inhibition of testosterone production in both the adrenals and the testes. Clinical studies demonstrated that CYP17 blockade by abiraterone acetate is safe and has significant antitumor activity in CRPC (castration-resistant prostate cancer).

June 21, 2017

prudect name : Abiraterone (CB-7598, CB7598, CB 7598) is a potent steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase (CYP17) inhibitor with an IC50 at 4 nM.
Abiraterone (CB-7598, CB7598, CB 7598) is currently undergoing phase II clinical trials as a potential compound for the treatment of prostate cancer. In preclinical studies, abiraterone (CB-7598, CB7598, CB 7598) has demonstrated the ability to selectively inhibit the target enzyme, resulting in inhibition of testosterone production in both the adrenals and the testes. Clinical studies demonstrated that CYP17 blockade by abiraterone acetate is safe and has significant antitumor activity in CRPC (castration-resistant prostate cancer).
Abiraterone (CB-7598)

Synonyms: Abiraterone (CB-7598)CAS NO: 154229-19-3Molecular Formula: C₂₄H₃₁NOMolecular Weight: 349.51Purity: 98% minSolubility: In DMSOStorage: −20°C

842133-18-0 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18496842